Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 1, 2013, Pages 46-60

  Subramaniam, Aruljothi ^a,b   Shanmugam, Muthu K ^a   Perumal, Ekambaram ^b   Li, Feng ^a   Nachiyappan, Alamelu ^a   Dai, Xiaoyun ^a   Swamy, Shivananju Nanjunda ^c   Ahn, Kwang Seok ^d   Kumar, Alan Prem ^a,e,f,g   Tan, Benny K H ^a   Hui, Kam Man ^h   Sethi, Gautam ^a,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b BHARATHIAR UNIVERSITY   (India)

^c SRI JAYACHAMARAJENDRA COLLEGE OF ENGINEERING   (India)

^d Kyung Hee University   (South Korea)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f CURTIN UNIVERSITY   (Australia)

^g UNIVERSITY OF NORTH TEXAS   (United States)

^h DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Apoptosis; Hepatocellular carcinoma; Invasion; JAKs; Proliferation; STAT3

Indexed keywords

17 HYDROXY JOLKINOLIDE B; 2 (1 CHLOROPROPENYL) 4,5 DIHYDROXY CYCLOPENT 2 ENOME; 2 METHOXYESTRA 1,3,5(10),16 TETRAENE 3 CARBOXAMIDE; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; ANTIPRIMOD; ANTISENSE OLIGONUCLEOTIDE; BETA ESCIN; BUTEIN; CELECOXIB; DIOSGENIN; GALIELLALACTONE; GAMMA TOCOTRIENOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JANUS KINASE; LIFICIGUAT; LUTEOLIN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PARTHENOLIDE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; SD 1029; SORAFENIB; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STATTIC; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; ENZYME REGULATION; GENE CONTROL; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INFLAMMATION; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84868693885     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.10.002     Document Type: Review

References (283)

1. Fausto N., Campbell J.S., Riehle K.J. Liver regeneration. Hepatology 2006, 43:S45-S53.
2. Lau W.Y., Lai E.C. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat. Dis. Int. 2008, 7:237-257.
3. Osada S., Saji S., Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J. Surg. Oncol. 2004, 85:48-54.
4. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
5. Block T.M., Mehta A.S., Fimmel C.J., Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22:5093-5107.
6. Lin L., Amin R., Gallicano G.I., Glasgow E., Jogunoori W., Jessup J.M., Zasloff M., Marshall J.L., Shetty K., Johnson L., Mishra L., He A.R. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009, 28:961-972.
7. Blum H.E. Hepatocellular carcinoma: therapy and prevention. World J. Gastroenterol. 2005, 11:7391-7400.
8. Bray F., Ferlay J., Pisani P., Parkin D.M. Cancer incidence, mortality and prevalence worldwide 2001, IARC press, Lyon. J. Ferlay (Ed.).
9. Seow T.K., Liang R.C., Leow C.K., Chung M.C. Hepatocellular carcinoma: from bedside to proteomics. Proteomics 2001, 1:1249-1263.
10. Wilson J.F. Liver cancer on the rise. Ann. Intern. Med. 2005, 142:1029-1032.
11. Nakamoto Y., Kaneko S. Mechanisms of viral hepatitis induced liver injury. Curr. Mol. Med. 2003, 3:537-544.
12. Herzer K., Sprinzl M.F., Galle P.R. Hepatitis viruses: live and let die. Liver Int. 2007, 27:293-301.
13. Tong M.J., el-Farra N.S., Reikes A.R., Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 1995, 332:1463-1466.
14. Hino O., Kajino K., Umeda T., Arakawa Y. Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J. Gastroenterol. 2002, 37:883-887.
15. Feitelson M.A., Reis H.M., Liu J., Lian Z., Pan J. Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis. Front. Biosci. 2005, 10:1558-1572.
16. Bouchard M.J., Schneider R.J. The enigmatic X gene of hepatitis B virus. J. Virol. 2004, 78:12725-12734.
17. Kekule A.S., Lauer U., Weiss L., Luber B., Hofschneider P.H. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993, 361:742-745.
18. Yeh C.T., Shen C.H., Tai D.I., Chu C.M., Liaw Y.F. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene 2000, 19:5213-5220.
19. Hsia C.C., Yuwen H., Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 1996, 348:625-626.
20. Becker S., Groner B., Muller C.W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998, 394:145-151.
21. Abe K., Edamoto Y., Park Y.N., Nomura A.M., Taltavull T.C., Tani M., Thung S.N. In situ detection of hepatitis B, C, and G virus nucleic acids in human hepatocellular carcinoma tissues from different geographic regions. Hepatology 1998, 28:568-572.
22. R. Beasley, Hepatitis B virus. The major etiology of hepatocelluar carcinoma, in: R.J. Fortner JC (Ed.) Accomplishment in Cancer Research 1987, JP Lippincot, 1988, Philadelphia, 1987.
23. Dubuisson J., Penin F., Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol. 2002, 12:517-523.
24. Bureau C., Bernad J., Chaouche N., Orfila C., Beraud M., Gonindard C., Alric L., Vinel J.P., Pipy B. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J. Biol. Chem. 2001, 276:23077-23083.
25. Gong G., Waris G., Tanveer R., Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9599-9604.
26. Roberts L.R., Gores G.J. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis. 2005, 25:212-225.
27. Wang L.Y., Chen C.J., Zhang Y.J., Tsai W.Y., Lee P.H., Feitelson M.A., Lee C.S., Santella R.M. 4-Aminobiphenyl DNA damage in liver tissue of hepatocellular carcinoma patients and controls. Am. J. Epidemiol. 1998, 147:315-323.
28. El-Serag H.B., Hampel H., Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 2006, 4:369-380.
29. Adams L.A., Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet. Med. 2005, 22:1129-1133.
30. Toffanin S., Friedman S.L., Llovet J.M. Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. Cancer Cell 2010, 17:115-117.
31. Fracanzani A.L., Conte D., Fraquelli M., Taioli E., Mattioli M., Losco A., Fargion S. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001, 33:647-651.
32. Elmberg M., Hultcrantz R., Ekbom A., Brandt L., Olsson S., Olsson R., Lindgren S., Loof L., Stal P., Wallerstedt S., Almer S., Sandberg-Gertzen H., Askling J. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003, 125:1733-1741.
33. Abdel-Wahab M., El-Ghawalby N., Mostafa M., Sultan A., El-Sadany M., Fathy O., Salah T., Ezzat F. Epidemiology of hepatocellular carcinoma in lower Egypt, Mansoura Gastroenterology Center. Hepatogastroenterology 2007, 54:157-162.
34. Qian G.S., Ross R.K., Yu M.C., Yuan J.M., Gao Y.T., Henderson B.E., Wogan G.N., Groopman J.D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 1994, 3:3-10.
35. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13:513-609.
36. Thomas D. Exagenous Steroid Hormones and Hepatocellular Carcinoma. Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America 1991, Gulf Publishing Company, Houston. A.D.B.E. Tabor, R.H. Purcell (Eds.).
37. Shuai K., Stark G.R., Kerr I.M., Darnell J.E. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993, 261:1744-1746.
38. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
39. Hou X.S., Perrimon N. The JAK-STAT pathway in Drosophila. Trends Genet. 1997, 13:105-110.
40. Yan R., Small S., Desplan C., Dearolf C.R., Darnell J.E. Identification of a Stat gene that functions in Drosophila development. Cell 1996, 84:421-430.
41. Ueno H., Sasaki K., Miyagawa K., Honda H., Mitani K., Yazaki Y., Hirai H. Antisense repression of proto-oncogene c-Cbl enhances activation of the JAK-STAT pathway but not the ras pathway in epidermal growth factor receptor signaling. J. Biol. Chem. 1997, 272:8739-8743.
42. Barillas-Mury C., Han Y.S., Seeley D., Kafatos F.C. Anopheles gambiae Ag-STAT, a new insect member of the STAT family, is activated in response to bacterial infection. EMBO J. 1999, 18:959-967.
43. Oates A.C., Wollberg P., Pratt S.J., Paw B.H., Johnson S.L., Ho R.K., Postlethwait J.H., Zon L.I., Wilks A.F. Zebrafish stat3 is expressed in restricted tissues during embryogenesis and stat1 rescues cytokine signaling in a STAT1-deficient human cell line. Dev. Dyn. 1999, 215:352-370.
44. Heim M. Signal Transducers and Activators of Transcription (STATs): Activation and Biology. The Stat protein family 2003, vol. 2:11-26. Kluwer Academic Publishers, The Netherlands. T. Hirano, P. Shegal (Eds.).
45. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109:1139-1142.
46. Copeland N.G., Gilbert D.J., Schindler C., Zhong Z., Wen Z., Darnell J.E., Mui A.L., Miyajima A., Quelle F.W., Ihle J.N., et al. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 1995, 29:225-228.
47. Strain A. Liver growth and repair 1998, Chapman and Hall, London.
48. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J. Clin. Invest. 2003, 112:978-980.
49. Costa R.H., Kalinichenko V.V., Holterman A.X., Wang X. Transcription factors in liver development, differentiation, and regeneration. Hepatology 2003, 38:1331-1347.
50. Mangnall D., Bird N.C., Majeed A.W. The molecular physiology of liver regeneration following partial hepatectomy. Liver Int. 2003, 23:124-138.
51. Wegenka U.M., Buschmann J., Lutticken C., Heinrich P.C., Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol. Cell. Biol. 1993, 13:276-288.
52. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
53. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., Gupta S.R., Tharakan S.T., Koca C., Dey S., Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann. N. Y. Acad. Sci. 2009, 1171:59-76.
54. Akira S., Nishio Y., Inoue M., Wang X.J., Wei S., Matsusaka T., Yoshida K., Sudo T., Naruto M., Kishimoto T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77:63-71.
55. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990, 63:1149-1157.
56. Hirano T., Nakajima K., Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997, 8:241-252.
57. Stahl N., Farruggella T.J., Boulton T.G., Zhong Z., Darnell J.E., Yancopoulos G.D. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995, 267:1349-1353.
58. Tilg H., Wilmer A., Vogel W., Herold M., Nolchen B., Judmaier G., Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992, 103:264-274.
59. Trikha M., Corringham R., Klein B., Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 2003, 9:4653-4665.
60. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
61. Kovalovich K., DeAngelis R.A., Li W., Furth E.E., Ciliberto G., Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 2000, 31:149-159.
62. Haga S., Terui K., Zhang H.Q., Enosawa S., Ogawa W., Inoue H., Okuyama T., Takeda K., Akira S., Ogino T., Irani K., Ozaki M. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J. Clin. Invest. 2003, 112:989-998.
63. Cressman D.E., Greenbaum L.E., DeAngelis R.A., Ciliberto G., Furth E.E., Poli V., Taub R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274:1379-1383.
64. Porta C., De Amici M., Quaglini S., Paglino C., Tagliani F., Boncimino A., Moratti R., Corazza G.R. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann. Oncol. 2008, 19:353-358.
65. Liu Y., Li P.K., Li C., Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem. 2010, 285:27429-27439.
66. Alonzi T., Maritano D., Gorgoni B., Rizzuto G., Libert C., Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol. Cell. Biol. 2001, 21:1621-1632.
67. Dumoutier L., Van Roost E., Colau D., Renauld J.C. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10144-10149.
68. Radaeva S., Sun R., Pan H.N., Hong F., Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004, 39:1332-1342.
69. Vignais M.L., Sadowski H.B., Watling D., Rogers N.C., Gilman M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol. Cell. Biol. 1996, 16:1759-1769.
70. Novak U., Harpur A.G., Paradiso L., Kanagasundaram V., Jaworowski A., Wilks A.F., Hamilton J.A. Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood 1995, 86:2948-2956.
71. Marrero M.B., Schieffer B., Paxton W.G., Heerdt L., Berk B.C., Delafontaine P., Bernstein K.E. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995, 375:247-250.
72. Guillet-Deniau I., Burnol A.F., Girard J. Identification and localization of a skeletal muscle secrotonin 5-HT2A receptor coupled to the Jak/STAT pathway. J. Biol. Chem. 1997, 272:14825-14829.
73. Welte T., Leitenberg D., Dittel B.N., al-Ramadi B.K., Xie B., Chin Y.E., Janeway C.A., Bothwell A.L., Bottomly K., Fu X.Y. STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation. Science 1999, 283:222-225.
74. Karras J.G., Wang Z., Huo L., Frank D.A., Rothstein T.L. Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J. Immunol. 1997, 159:4350-4355.
75. Sachsenmaier C., Sadowski H.B., Cooper J.A. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation. Oncogene 1999, 18:3583-3592.
76. Wang Y.Z., Wharton W., Garcia R., Kraker A., Jove R., Pledger W.J. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 2000, 19:2075-2085.
77. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
78. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002, 31:339-346.
79. Libbrecht L., Desmet V., Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int. 2005, 25:16-27.
80. Lee Y.H., Yun Y. HBx protein of hepatitis B virus activates Jak1-STAT signaling. J. Biol. Chem. 1998, 273:25510-25515.
81. Germain D., Frank D.A. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 2007, 13:5665-5669.
82. Vinkemeier U., Moarefi I., Darnell J.E., Kuriyan J. Structure of the amino-terminal protein interaction domain of STAT-4. Science 1998, 279:1048-1052.
83. John S., Vinkemeier U., Soldaini E., Darnell J.E., Leonard W.J. The significance of tetramerization in promoter recruitment by Stat5. Mol. Cell. Biol. 1999, 19:1910-1918.
84. Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., Gritsko T., Turkson J., Kay H., Semenza G.L., Cheng J.Q., Jove R., Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24:5552-5560.
85. Collum R.G., Brutsaert S., Lee G., Schindler C. A Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10120-10125.
86. Zhang T., Seow K.T., Ong C.T., Cao X. Interdomain interaction of Stat3 regulates its Src homology 2 domain-mediated receptor binding activity. J. Biol. Chem. 2002, 277:17556-17563.
87. Horvath C.M. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem. Sci. 2000, 25:496-502.
88. Ma J., Cao X. Regulation of Stat3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cell. Signal. 2006, 18:1117-1126.
89. Shuai K. The STAT family of proteins in cytokine signaling. Prog. Biophys. Mol. Biol. 1999, 71:405-422.
90. Neel B.G., Tonks N.K. Protein tyrosine phosphatases in signal transduction. Curr. Opin. Cell Biol. 1997, 9:193-204.
91. Imada K., Leonard W.J. The Jak-STAT pathway. Mol. Immunol. 2000, 37:1-11.
92. Rane S.G., Reddy E.P. JAKs, STATs and Src kinases in hematopoiesis. Oncogene 2002, 21:3334-3358.
93. Pellegrini S., Dusanter-Fourt I. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur. J. Biochem. 1997, 248:615-633.
94. Hilkens C.M., Is'harc H., Lillemeier B.F., Strobl B., Bates P.A., Behrmann I., Kerr I.M. A region encompassing the FERM domain of Jak1 is necessary for binding to the cytokine receptor gp130. FEBS Lett. 2001, 505:87-91.
95. Zhou Y.J., Chen M., Cusack N.A., Kimmel L.H., Magnuson K.S., Boyd J.G., Lin W., Roberts J.L., Lengi A., Buckley R.H., Geahlen R.L., Candotti F., Gadina M., Changelian P.S., O'Shea J.J. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell 2001, 8:959-969.
96. Higgins D.G., Thompson J.D., Gibson T.J. Using CLUSTAL for multiple sequence alignments. Methods Enzymol. 1996, 266:383-402.
97. Kampa D., Burnside J. Computational and functional analysis of the putative SH2 domain in Janus Kinases. Biochem. Biophys. Res. Commun. 2000, 278:175-182.
98. Haan C., Kreis S., Margue C., Behrmann I. Jaks and cytokine receptors-an intimate relationship. Biochem. Pharmacol. 2006, 72:1538-1546.
99. Richter M.F., Dumenil G., Uze G., Fellous M., Pellegrini S. Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1. J. Biol. Chem. 1998, 273:24723-24729.
100. Haan C., Heinrich P.C., Behrmann I. Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. Biochem. J. 2002, 361:105-111.
101. Gauzzi M.C., Barbieri G., Richter M.F., Uze G., Ling L., Fellous M., Pellegrini S. The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11839-11844.
102. Ragimbeau J., Dondi E., Alcover A., Eid P., Uze G., Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 2003, 22:537-547.
103. Huang L.J., Constantinescu S.N., Lodish H.F. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell 2001, 8:1327-1338.
104. Rodig S.J., Meraz M.A., White J.M., Lampe P.A., Riley J.K., Arthur C.D., King K.L., Sheehan K.C., Yin L., Pennica D., Johnson E.M., Schreiber R.D. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
105. Nosaka T., van Deursen J.M., Tripp R.A., Thierfelder W.E., Witthuhn B.A., McMickle A.P., Doherty P.C., Grosveld G.C., Ihle J.N. Defective lymphoid development in mice lacking Jak3. Science 1995, 270:800-802.
106. Thomis D.C., Gurniak C.B., Tivol E., Sharpe A.H., Berg L.J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995, 270:794-797.
107. Brown M.T., Cooper J.A. Regulation, substrates and functions of src. Biochim. Biophys. Acta 1996, 1287:121-149.
108. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R.P., Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 1998, 18:2545-2552.
109. Martin G.S. The hunting of the Src. Nat. Rev. Mol. Cell Biol. 2001, 2:467-475.
110. Weng Z., Thomas S.M., Rickles R.J., Taylor J.A., Brauer A.W., Seidel-Dugan C., Michael W.M., Dreyfuss G., Brugge J.S. Identification of Src, Fyn, and Lyn SH3-binding proteins: implications for a function of SH3 domains. Mol. Cell. Biol. 1994, 14:4509-4521.
111. Briggs S.D., Bryant S.S., Jove R., Sanderson S.D., Smithgall T.E. The Ras GTPase-activating protein (GAP) is an SH3 domain-binding protein and substrate for the Src-related tyrosine kinase, Hck. J. Biol. Chem. 1995, 270:14718-14724.
112. Superti-Furga G., Fumagalli S., Koegl M., Courtneidge S.A., Draetta G. Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J. 1993, 12:2625-2634.
113. Murphy S.M., Bergman M., Morgan D.O. Suppression of c-Src activity by C-terminal Src kinase involves the c-Src SH2 and SH3 domains: analysis with Saccharomyces cerevisiae. Mol. Cell. Biol. 1993, 13:5290-5300.
114. Okada M., Howell B.W., Broome M.A., Cooper J.A. Deletion of the SH3 domain of Src interferes with regulation by the phosphorylated carboxyl-terminal tyrosine. J. Biol. Chem. 1993, 268:18070-18075.
115. Kuriyan J., Cowburn D. Modular peptide recognition domains in eukaryotic signaling. Annu. Rev. Biophys. Biomol. Struct. 1997, 26:259-288.
116. Waksman G., Shoelson S.E., Pant N., Cowburn D., Kuriyan J. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 1993, 72:779-790.
117. Koegl M., Zlatkine P., Ley S.C., Courtneidge S.A., Magee A.I. Palmitoylation of multiple Src-family kinases at a homologous N-terminal motif. Biochem. J. 1994, 303(Pt 3):749-753.
118. Resh M.D. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim. Biophys. Acta 1999, 1451:1-16.
119. Summy J.M., Qian Y., Jiang B.H., Guappone-Koay A., Gatesman A., Shi X., Flynn D.C. The SH4-Unique-SH3-SH2 domains dictate specificity in signaling that differentiate c-Yes from c-Src. J. Cell Sci. 2003, 116:2585-2598.
120. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
121. Reich N.C., Liu L. Tracking STAT nuclear traffic. Nat. Rev. Immunol. 2006, 6:602-612.
122. Ihle J.N. Cytokine receptor signalling. Nature 1995, 377:591-594.
123. Schindler C., Darnell J.E. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 1995, 64:621-651.
124. Zeidler M.P., Bach E.A., Perrimon N. The roles of the Drosophila JAK/STAT pathway. Oncogene 2000, 19:2598-2606.
125. Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19:2548-2556.
126. Smithgall T.E., Briggs S.D., Schreiner S., Lerner E.C., Cheng H., Wilson M.B. Control of myeloid differentiation and survival by Stats. Oncogene 2000, 19:2612-2618.
127. Mui A.L. The role of STATs in proliferation, differentiation, and apoptosis. Cell. Mol. Life Sci. 1999, 55:1547-1558.
128. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzki A., Kraker A., Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
129. Gouilleux-Gruart V., Gouilleux F., Desaint C., Claisse J.F., Capiod J.C., Delobel J., Weber-Nordt R., Dusanter-Fourt I., Dreyfus F., Groner B., Prin L. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996, 87:1692-1697.
130. Alvarez J.V., Febbo P.G., Ramaswamy S., Loda M., Richardson A., Frank D.A. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005, 65:5054-5062.
131. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005, 65:10794-10800.
132. Kanda N., Seno H., Konda Y., Marusawa H., Kanai M., Nakajima T., Kawashima T., Nanakin A., Sawabu T., Uenoyama Y., Sekikawa A., Kawada M., Suzuki K., Kayahara T., Fukui H., Sawada M., Chiba T. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004, 23:4921-4929.
133. Xie T.X., Huang F.J., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., Xie K., Sawaya R., Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006, 66:3188-3196.
134. Qiu Z., Huang C., Sun J., Qiu W., Zhang J., Li H., Jiang T., Huang K., Cao J. RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci. 2007, 98:1099-1106.
135. Morita Y., Naka T., Kawazoe Y., Fujimoto M., Narazaki M., Nakagawa R., Fukuyama H., Nagata S., Kishimoto T. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5405-5410.
136. Gamero A.M., Young H.A., Wiltrout R.H. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?. Cancer Cell 2004, 5:111-112.
137. Yue P., Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin. Investig. Drugs 2009, 18:45-56.
138. Ihle J.N. STATs: signal transducers and activators of transcription. Cell 1996, 84:331-334.
139. Hemmann U., Gerhartz C., Heesel B., Sasse J., Kurapkat G., Grotzinger J., Wollmer A., Zhong Z., Darnell J.E., Graeve L., Heinrich P.C., Horn F. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem. 1996, 271:12999-13007.
140. Ehret G.B., Reichenbach P., Schindler U., Horvath C.M., Fritz S., Nabholz M., Bucher P. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J. Biol. Chem. 2001, 276:6675-6688.
141. Wen Z., Darnell J.E. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997, 25:2062-2067.
142. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
143. Herrmann A., Vogt M., Monnigmann M., Clahsen T., Sommer U., Haan S., Poli V., Heinrich P.C., Muller-Newen G. Nucleocytoplasmic shuttling of persistently activated STAT3. J. Cell Sci. 2007, 120:3249-3261.
144. Pranada A.L., Metz S., Herrmann A., Heinrich P.C., Muller-Newen G. Real time analysis of STAT3 nucleocytoplasmic shuttling. J. Biol. Chem. 2004, 279:15114-15123.
145. Sato N., Tsuruma R., Imoto S., Sekine Y., Muromoto R., Sugiyama K., Matsuda T. Nuclear retention of STAT3 through the coiled-coil domain regulates its activity. Biochem. Biophys. Res. Commun. 2005, 336:617-624.
146. ten Hoeve J., de Jesus Ibarra-Sanchez M., Fu Y., Zhu W., Tremblay M., David M., Shuai K. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell. Biol. 2002, 22:5662-5668.
147. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., Kishimoto T., Akira S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3801-3804.
148. Matsuda T., Nakamura T., Nakao K., Arai T., Katsuki M., Heike T., Yokota T. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 1999, 18:4261-4269.
149. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000, 19:2607-2611.
150. Li W., Liang X., Kellendonk C., Poli V., Taub R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J. Biol. Chem. 2002, 277:28411-28417.
151. Inoue H., Ogawa W., Ozaki M., Haga S., Matsumoto M., Furukawa K., Hashimoto N., Kido Y., Mori T., Sakaue H., Teshigawara K., Jin S., Iguchi H., Hiramatsu R., LeRoith D., Takeda K., Akira S., Kasuga M. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 2004, 10:168-174.
152. Hauser P.J., Agrawal D., Hackney J., Pledger W.J. STAT3 activation accompanies keratinocyte differentiation. Cell Growth Differ. 1998, 9:847-855.
153. Shimozaki K., Nakajima K., Hirano T., Nagata S. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J. Biol. Chem. 1997, 272:25184-25189.
154. Boccaccio C., Ando M., Tamagnone L., Bardelli A., Michieli P., Battistini C., Comoglio P.M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998, 391:285-288.
155. Sano S., Chan K.S., Carbajal S., Clifford J., Peavey M., Kiguchi K., Itami S., Nickoloff B.J., DiGiovanni J. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 2005, 11:43-49.
156. Sano S., Itami S., Takeda K., Tarutani M., Yamaguchi Y., Miura H., Yoshikawa K., Akira S., Takeda J. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999, 18:4657-4668.
157. Chapman R.S., Lourenco P.C., Tonner E., Flint D.J., Selbert S., Takeda K., Akira S., Clarke A.R., Watson C.J. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 1999, 13:2604-2616.
158. Takeda K., Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 2000, 11:199-207.
159. Yoo J.Y., Huso D.L., Nathans D., Desiderio S. Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell 2002, 108:331-344.
160. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
161. Bromberg J., Darnell J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
162. Kubo M., Hanada T., Yoshimura A. Suppressors of cytokine signaling and immunity. Nat. Immunol. 2003, 4:1169-1176.
163. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 2000, 19:2638-2644.
164. Yoshimura A., Ohkubo T., Kiguchi T., Jenkins N.A., Gilbert D.J., Copeland N.G., Hara T., Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 1995, 14:2816-2826.
165. Alexander W.S., Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 2004, 22:503-529.
166. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A., Hilton D.J. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921.
167. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., Matsumoto A., Tanimura S., Ohtsubo M., Misawa H., Miyazaki T., Leonor N., Taniguchi T., Fujita T., Kanakura Y., Komiya S., Yoshimura A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997, 387:921-924.
168. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., Nishimoto N., Kajita T., Taga T., Yoshizaki K., Akira S., Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997, 387:924-929.
169. Hilton D.J., Richardson R.T., Alexander W.S., Viney E.M., Willson T.A., Sprigg N.S., Starr R., Nicholson S.E., Metcalf D., Nicola N.A. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:114-119.
170. Bjorbaek C., Elmquist J.K., Frantz J.D., Shoelson S.E., Flier J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell 1998, 1:619-625.
171. Bjorbaek C., El-Haschimi K., Frantz J.D., Flier J.S. The role of SOCS-3 in leptin signaling and leptin resistance. J. Biol. Chem. 1999, 274:30059-30065.
172. Emilsson V., Arch J.R., de Groot R.P., Lister C.A., Cawthorne M.A. Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett. 1999, 455:170-174.
173. Narazaki M., Fujimoto M., Matsumoto T., Morita Y., Saito H., Kajita T., Yoshizaki K., Naka T., Kishimoto T. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13130-13134.
174. Kamura T., Sato S., Haque D., Liu L., Kaelin W.G., Conaway R.C., Conaway J.W. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 1998, 12:3872-3881.
175. Zhang J.G., Farley A., Nicholson S.E., Willson T.A., Zugaro L.M., Simpson R.J., Moritz R.L., Cary D., Richardson R., Hausmann G., Kile B.J., Kent S.B., Alexander W.S., Metcalf D., Hilton D.J., Nicola N.A., Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2071-2076.
176. Kamizono S., Hanada T., Yasukawa H., Minoguchi S., Kato R., Minoguchi M., Hattori K., Hatakeyama S., Yada M., Morita S., Kitamura T., Kato H., Nakayama K., Yoshimura A. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 2001, 276:12530-12538.
177. Sasaki A., Inagaki-Ohara K., Yoshida T., Yamanaka A., Sasaki M., Yasukawa H., Koromilas A.E., Yoshimura A. The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6. J. Biol. Chem. 2003, 278:2432-2436.
178. Campbell J.S., Prichard L., Schaper F., Schmitz J., Stephenson-Famy A., Rosenfeld M.E., Argast G.M., Heinrich P.C., Fausto N. Expression of suppressors of cytokine signaling during liver regeneration. J. Clin. Invest. 2001, 107:1285-1292.
179. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., Harris C.C., Herman J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 2001, 28:29-35.
180. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005, 24:6406-6417.
181. Torisu T., Nakaya M., Watanabe S., Hashimoto M., Yoshida H., Chinen T., Yoshida R., Okamoto F., Hanada T., Torisu K., Takaesu G., Kobayashi T., Yasukawa H., Yoshimura A. Suppressor of cytokine signaling 1 protects mice against concanavalin A-induced hepatitis by inhibiting apoptosis. Hepatology 2008, 47:1644-1654.
182. Bagnyukova T.V., Tryndyak V.P., Muskhelishvili L., Ross S.A., Beland F.A., Pogribny I.P. Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats. Cell Cycle 2008, 7:3202-3210.
183. Jackson P.K. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev. 2001, 15:3053-3058.
184. Shuai K., Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 2005, 5:593-605.
185. Chung C.D., Liao J., Liu B., Rao X., Jay P., Berta P., Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997, 278:1803-1805.
186. Shuai K., Liu B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 2003, 3:900-911.
187. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., Factor V.M., Thorgeirsson S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
188. Wu C., Guan Q., Wang Y., Zhao Z.J., Zhou G.W. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J. Cell. Biochem. 2003, 90:1026-1037.
189. Al Zaid Siddiquee K., Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008, 18:254-267.
190. Cao X., Tay A., Guy G.R., Tan Y.H. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 1996, 16:1595-1603.
191. Chaturvedi P., Sharma S., Reddy E.P. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell. Biol. 1997, 17:3295-3304.
192. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., Darnell J.E. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 1998, 18:2553-2558.
193. Song J.I., Grandis J.R. STAT signaling in head and neck cancer. Oncogene 2000, 19:2489-2495.
194. Grandis J.R., Drenning S.D., Chakraborty A., Zhou M.Y., Zeng Q., Pitt A.S., Tweardy D.J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J. Clin. Invest. 1998, 102:1385-1392.
195. Li W.C., Ye S.L., Sun R.X., Liu Y.K., Tang Z.Y., Kim Y., Karras J.G., Zhang H. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin. Cancer Res. 2006, 12:7140-7148.
196. Tannapfel A., Anhalt K., Hausermann P., Sommerer F., Benicke M., Uhlmann D., Witzigmann H., Hauss J., Wittekind C. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J. Pathol. 2003, 201:238-249.
197. Feng D.Y., Zheng H., Tan Y., Cheng R.X. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J. Gastroenterol. 2001, 7:33-36.
198. Sanchez A., Nagy P., Thorgeirsson S.S. STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur. J. Cancer 2003, 39:2093-2098.
199. Thorgeirsson U.P., Dalgard D.W., Reeves J., Adamson R.H. Tumor incidence in a chemical carcinogenesis study of nonhuman primates. Regul. Toxicol. Pharmacol. 1994, 19:130-151.
200. Rebouissou S., Amessou M., Couchy G., Poussin K., Imbeaud S., Pilati C., Izard T., Balabaud C., Bioulac-Sage P., Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204.
201. Yang S.F., Wang S.N., Wu C.F., Yeh Y.T., Chai C.Y., Chunag S.C., Sheen M.C., Lee K.T. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J. Clin. Pathol. 2007, 60:642-648.
202. Yeoh G.C., Ernst M., Rose-John S., Akhurst B., Payne C., Long S., Alexander W., Croker B., Grail D., Matthews V.B. Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation. Hepatology 2007, 45:486-494.
203. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
204. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., Margolick J.B., Liotta L.A., Petricoin E., Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16158-16163.
205. He G., Yu G.Y., Temkin V., Ogata H., Kuntzen C., Sakurai T., Sieghart W., Peck-Radosavljevic M., Leffert H.L., Karin M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010, 17:286-297.
206. He G., Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011, 21:159-168.
207. Pfitzner E., Kliem S., Baus D., Litterst C.M. The role of STATs in inflammation and inflammatory diseases. Curr. Pharm. Des. 2004, 10:2839-2850.
208. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D.M., Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293.
209. Nadiminty N., Lou W., Lee S.O., Lin X., Trump D.L., Gao A.C. Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7264-7269.
210. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21:11-19.
211. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
212. Wang C., Yang W., Yan H.X., Luo T., Zhang J., Tang L., Wu F.Q., Zhang H.L., Yu L.X., Zheng L.Y., Li Y.Q., Dong W., He Y.Q., Liu Q., Zou S.S., Lin Y., Hu L., Li Z., Wu M.C., Wang H.Y. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology 2012, 55:108-120.
213. Wang X.H., Sun X., Meng X.W., Lv Z.W., Du Y.J., Zhu Y., Chen J., Kong D.X., Jin S.Z. beta-catenin siRNA regulation of apoptosis- and angiogenesis-related gene expression in hepatocellular carcinoma cells: potential uses for gene therapy. Oncol. Rep. 2010, 24:1093-1099.
214. Ji J., Wang X.W. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin. Oncol. 2012, 39:461-472.
215. Yuan F., Zhou W., Zou C., Zhang Z., Hu H., Dai Z., Zhang Y. Expression of Oct4 in HCC and modulation to wnt/beta-catenin and TGF-beta signal pathways. Mol. Cell. Biochem. 2010, 343:155-162.
216. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
217. Niu G., Heller R., Catlett-Falcone R., Coppola D., Jaroszeski M., Dalton W., Jove R., Yu H. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999, 59:5059-5063.
218. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., Li Y., Wang J.M., Yang-Yen H.F., Karras J., Jove R., Loughran T.P. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 2001, 107:351-362.
219. Fuke H., Shiraki K., Sugimoto K., Tanaka J., Beppu T., Yoneda K., Yamamoto N., Ito K., Masuya M., Takei Y. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2007, 363:738-744.
220. Shiraki K., Sugimoto K., Yamanaka Y., Yamaguchi Y., Saitou Y., Ito K., Yamamoto N., Yamanaka T., Fujikawa K., Murata K., Nakano T. Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int. J. Mol. Med. 2003, 12:705-708.
221. Jing N., Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16:601-607.
222. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., Takase K., Moriyama M., Kawano H., Hayashida M., Nakano T., Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000, 31:1080-1085.
223. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett. 2007, 249:49-60.
224. Kusaba M., Nakao K., Goto T., Nishimura D., Kawashimo H., Shibata H., Motoyoshi Y., Taura N., Ichikawa T., Hamasaki K., Eguchi K. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J. Hepatol. 2007, 47:546-555.
225. Masaki T., Shiratori Y., Rengifo W., Igarashi K., Yamagata M., Kurokohchi K., Uchida N., Miyauchi Y., Yoshiji H., Watanabe S., Omata M., Kuriyama S. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 2003, 37:534-543.
226. Matsuda Y., Ichida T., Genda T., Yamagiwa S., Aoyagi Y., Asakura H. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin. Cancer Res. 2003, 9:3389-3396.
227. Matsuda Y., Ichida T. p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med. Mol. Morphol. 2006, 39:169-175.
228. Rak J., Filmus J., Kerbel R.S. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur. J. Cancer 1996, 32A:2438-2450.
229. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
230. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 1999, 9:211-220.
231. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60:203-212.
232. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
233. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
234. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367:576-579.
235. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 1999, 59:1592-1598.
236. Poon R.T., Ng I.O., Lau C., Yu W.C., Fan S.T., Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am. J. Surg. 2001, 182:298-304.
237. Torimura T., Sata M., Ueno T., Kin M., Tsuji R., Suzaku K., Hashimoto O., Sugawara H., Tanikawa K. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum. Pathol. 1998, 29:986-991.
238. Miura H., Miyazaki T., Kuroda M., Oka T., Machinami R., Kodama T., Shibuya M., Makuuchi M., Yazaki Y., Ohnishi S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol. 1997, 27:854-861.
239. El-Assal O.N., Yamanoi A., Soda Y., Yamaguchi M., Igarashi M., Yamamoto A., Nabika T., Nagasue N. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998, 27:1554-1562.
240. Devarajan E., Huang S. STAT3 as a central regulator of tumor metastases. Curr. Mol. Med. 2009, 9:626-633.
241. Gotzmann J., Fischer A.N., Zojer M., Mikula M., Proell V., Huber H., Jechlinger M., Waerner T., Weith A., Beug H., Mikulits W. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 2006, 25:3170-3185.
242. Fischer A.N., Fuchs E., Mikula M., Huber H., Beug H., Mikulits W. PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 2007, 26:3395-3405.
243. Campbell J.S., Hughes S.D., Gilbertson D.G., Palmer T.E., Holdren M.S., Haran A.C., Odell M.M., Bauer R.L., Ren H.P., Haugen H.S., Yeh M.M., Fausto N. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3389-3394.
244. Czochra P., Klopcic B., Meyer E., Herkel J., Garcia-Lazaro J.F., Thieringer F., Schirmacher P., Biesterfeld S., Galle P.R., Lohse A.W., Kanzler S. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J. Hepatol. 2006, 45:419-428.
245. Borkham-Kamphorst E., van Roeyen C.R., Ostendorf T., Floege J., Gressner A.M., Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J. Hepatol. 2007, 46:1064-1074.
246. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
247. Debidda M., Wang L., Zang H., Poli V., Zheng Y. A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J. Biol. Chem. 2005, 280:17275-17285.
248. Faruqi T.R., Gomez D., Bustelo X.R., Bar-Sagi D., Reich N.C. Rac1 mediates STAT3 activation by autocrine IL-6. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9014-9019.
249. Pelletier S., Duhamel F., Coulombe P., Popoff M.R., Meloche S. Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors. Mol. Cell. Biol. 2003, 23:1316-1333.
250. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
251. Ye Q.H., Qin L.X., Forgues M., He P., Kim J.W., Peng A.C., Simon R., Li Y., Robles A.I., Chen Y., Ma Z.C., Wu Z.Q., Ye S.L., Liu Y.K., Tang Z.Y., Wang X.W. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 2003, 9:416-423.
252. Dien J., Amin H.M., Chiu N., Wong W., Frantz C., Chiu B., Mackey J.R., Lai R. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am. J. Pathol. 2006, 169:633-642.
253. Gaemers I.C., Vos H.L., Volders H.H., van der Valk S.W., Hilkens J. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J. Biol. Chem. 2001, 276:6191-6199.
254. Liu Y., Liu A., Li H., Li C., Lin J. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev. Res. (Phila.) 2011, 4:1296-1305.
255. Liu Y., Liu A., Xu Z., Yu W., Wang H., Li C., Lin J. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Apoptosis 2011, 16:502-510.
256. Liu Y., Fuchs J., Li C., Lin J. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle 2010, 9:3423-3427.
257. Moser C., Lang S.A., Mori A., Hellerbrand C., Schlitt H.J., Geissler E.K., Fogler W.E., Stoeltzing O. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 2008, 8:206.
258. Fletcher S., Turkson J., Gunning P.T. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008, 3:1159-1168.
259. Li F., Fernandez P.P., Rajendran P., Hui K.M., Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010, 292:197-207.
260. Tan S.M., Li F., Rajendran P., Kumar A.P., Hui K.M., Sethi G. Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 2010, 334:285-293.
261. Rajendran P., Ong T.H., Chen L., Li F., Shanmugam M.K., Vali S., Abbasi T., Kapoor S., Sharma A., Kumar A.P., Hui K.M., Sethi G. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin. Cancer Res. 2011, 17:1425-1439.
262. Rajendran P., Li F., Manu K.A., Shanmugam M.K., Loo S.Y., Kumar A.P., Sethi G. gamma-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br. J. Pharmacol. 2011, 163:283-298.
263. Rajendran P., Li F., Shanmugam M.K., Vali S., Abbasi T., Kapoor S., Ahn K.S., Kumar A.P., Sethi G. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J. Cell. Physiol. 2012, 227:2184-2195.
264. Rajendran P., Li F., Shanmugam M.K., Kannaiyan R., Goh J.N., Wong K.F., Wang W., Khin E., Tergaonkar V., Kumar A.P., Luk J.M., Sethi G. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev. Res. (Phila.) 2012, 5:631-643.
265. Chen K.F., Su J.C., Liu C.Y., Huang J.W., Chen K.C., Chen W.L., Tai W.T., Shiau C.W. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Cancer Lett. 2012, 321:27-35.
266. Gu F.M., Li Q.L., Gao Q., Jiang J.H., Huang X.Y., Pan J.F., Fan J., Zhou J. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J. Gastroenterol. 2011, 17:3922-3932.
267. Tai W.T., Cheng A.L., Shiau C.W., Liu C.Y., Ko C.H., Lin M.W., Chen P.J., Chen K.F. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol. Cancer Ther. 2012, 11:452-463.
268. Page B.D., Ball D.P., Gunning P.T. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin. Ther. Pat. 2011, 21:65-83.
269. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 2006, 72:1605-1621.
270. Weidler M., Rether J., Anke T., Erkel G. Inhibition of interleukin-6 signaling and Stat3 activation by a new class of bioactive cyclopentenone derivatives. Biochem. Biophys. Res. Commun. 2000, 276:447-453.
271. Schust J., Sperl B., Hollis A., Mayer T.U., Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 2006, 13:1235-1242.
272. Carlisi D., D'Anneo A., Angileri L., Lauricella M., Emanuele S., Santulli A., Vento R., Tesoriere G. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J. Cell. Physiol. 2011, 226:1632-1641.
273. Lavecchia A., Di Giovanni C., Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr. Med. Chem. 2011, 18:2359-2375.
274. Duan Z., Bradner J.E., Greenberg E., Levine R., Foster R., Mahoney J., Seiden M.V. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin. Cancer Res. 2006, 12:6844-6852.
275. Tai W.T., Cheng A.L., Shiau C.W., Huang H.P., Huang J.W., Chen P.J., Chen K.F. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J. Hepatol. 2011, 55:1041-1048.
276. Chen K.F., Tai W.T., Liu T.H., Huang H.P., Lin Y.C., Shiau C.W., Li P.K., Chen P.J., Cheng A.L. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 2010, 16:5189-5199.
277. Won C., Lee C.S., Lee J.K., Kim T.J., Lee K.H., Yang Y.M., Kim Y.N., Ye S.K., Chung M.H. CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation. Anticancer. Res. 2010, 30:481-488.
278. Wang Y., Ma X., Yan S., Shen S., Zhu H., Gu Y., Wang H., Qin G., Yu Q. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. Cancer Res. 2009, 69:7302-7310.
279. Metz S., Wiesinger M., Vogt M., Lauks H., Schmalzing G., Heinrich P.C., Muller-Newen G. Characterization of the interleukin (IL)-6 inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins. J. Biol. Chem. 2007, 282:1238-1248.
280. Lau C.K., Yang Z.F., Lam S.P., Lam C.T., Ngai P., Tam K.H., Poon R.T., Fan S.T. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol. Ther. 2007, 6:1900-1907.
281. Choudhari S.R., Khan M.A., Harris G., Picker D., Jacob G.S., Block T., Shailubhai K. Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol. Cancer Ther. 2007, 6:112-121.
282. Selvendiran K., Koga H., Ueno T., Yoshida T., Maeyama M., Torimura T., Yano H., Kojiro M., Sata M. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res. 2006, 66:4826-4834.
283. Arnaud C., Burger F., Steffens S., Veillard N.R., Nguyen T.H., Trono D., Mach F. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1231-1236.